Various studies have shown that SFTA1P is involved in the progression in many tumors.[27–30] In papillary thyroid cancer (PTC), SFTA1P is the main constituents of competing endogenous lncRNA, and involved in the formation of PTC.[21] Meanwhile, SFTA1P also action as competing endogenous RNA in head and neck squamous cell carcinoma.[31] In hepatocellular carcinoma, AFTA1P could accelerate the tumor proliferation by down regulating mi4766-5p.[32] Li et al[33] and Xiong et al[34] have shown that SFTA1P associated with prognosis and cisplatin chemosensitivity in lung squamous cell carcinoma. The gene discussed is SFTA1P; the disease is thyroid gland papillary carcinoma.